Cannabinoid Drugs-Related Neuroprotection as a Potential Therapeutic Tool Against Chemotherapy-Induced Cognitive Impairment
Boullon, Pharmacology, Therapeutics, School Of Medicine, National University Of Ireland, Centre For Pain Research, Galway Neuroscience Centre, Abalo, Rea De Farmacolog A Y Nutrici N, Departamento De Ciencias B Sicas De La Salud
Summary of cognitive deficits induced by chemotherapeutic drugs in preclinical animal models of chemotherapy-induced cognitive impairment (CICI). Several studies have observed that the activation of CB 2 receptors decrease neuroinflammation in animal models of AD (Uddin et al., 2020). Activation of CB 2 receptors by GP1a (a CB 2 receptor agonist) induced a significant decrease in the levels of pro-inflammatory cytokines as well as an increase in the number of M2 macrophages in a TBI animal model (Braun et al., 2018). CBD administration also reduces the oxidant effects of chemotherapy drugs. Insights into the Effects of the Endocannabinoid System in Cancer: a Review.
Tags:
- Cannabinoid receptor type 2
- Post-chemotherapy cognitive impairment
- Reactive oxygen species
- Cannabinoid receptor
- Cannabinoid receptor type 1
- Neuroinflammation
- Chemotherapy
- Endocannabinoid system
- Neurodegenerative disease
- Inflammation
- Cancer
- Tetrahydrocannabinol
- Glioblastoma
- Angiogenesis
- Cannabinoid
- Cannabidiol
- 2-Arachidonoylglycerol
- Microglia
- Receptor (biochemistry)
- Memory
- Animal disease model
- Traumatic brain injury
- Clinical medicine
- Neuroscience
- Medical specialties
- Medicine
- Biochemistry